1M6MYTD1Å5ÅMAKS.
Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Nyheder Til nyhedsfeedet
SenzaGen achieves 13% revenue growth in second quarter thanks to recovery at VitroScreen
SenzaGen reports a 13% increase in revenue in the second quarter to SEK 15.3 million, driven by a recovery at subsidiary VitroScreen and two large orders. The operating loss narrowed, earnings per share improved compared with the previous year, and operating cash flow was positive. The company maintained a stable gross margin, cited effective cost management, and expects EU regulations reducing animal testing to support long-term demand for its test solutions. » Mere på de.investing.com
Virksomhedstal
| (EUR) | juni 2026 | |
|---|---|---|
| Omsætning | 1,38 mio. | 13,78 % |
| Bruttofortjeneste | 914,91 t | 18,09 % |
| Nettoresultat | -200,15 t | 58,00 % |
| EBITDA | -149,61 t | 57,72 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 14,39 mio. € |
Antal aktier | 32,51 mio. |
Højeste/laveste i 52 uger | 0,61 € - 0,41 € |
| Udbytte | Nej |
Beta | 0,58 |
P/E (PE Ratio) | -14,31 |
PEG (PEG Ratio) | -0,30 |
K/I (PB Ratio) | 1,81 |
P/S (PS Ratio) | 2,66 |
Virksomhedsprofil
| Navn | SENZAGEN AB |
| CEO | Peter Nahlstedt |
| Medarbejdere | 34 |
